134 completed, 30 terminated, 26 unknown, 19 active not recruiting. 233 Phase 3, 25 Phase 2.
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-11-18 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera AG-236, Placebo - Polycythemia Vera | Phase 2 / Phase 3 | Not yet recruiting | Agios Pharmaceuticals, Inc. | 245 | 2026-11-01 | 2026-10-13 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-29 | 2026-11-13 |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-11-06 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-11-13 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 460 | 2026-05-27 | 2026-11-17 |
| INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) Sapablursen, Placebo - Polycythemia Vera | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 250 | 2026-05-25 | 2026-10-29 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients TGRX-678, TKI - Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Not yet recruiting | Shenzhen TargetRx Co., Ltd. | 180 | 2026-04-01 | 2026-03-24 |
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk Ropeginterferon alfa-2b, Placebo - Primary Myelofibrosis, Myeloproliferative Neoplasm | Phase 3 | Active not recruiting | PharmaEssentia | 160 | 2025-07-18 | 2026-08-13 |
| Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance 81-mg aspirin once daily, 81-mg aspirin twice daily - Myeloproliferative Neoplasms (MPN) | Phase 3 | Recruiting | Siriraj Hospital | 240 | 2024-12-12 | 2024-12-27 |
| Platelet Transfusion in Critically Ill Patients With Thrombocytopenia Platelet transfusion if platelet count ≤ 10 G/L, Platelet transfusion when platelet count ≤ 20 G/L - Thrombocythemia | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 536 | 2024-11-01 | 2024-09-19 |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2024-07-16 | 2026-08-27 |
| Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib Navtemadlin, Navtemadlin placebo, Ruxolitinib - Myelofibrosis, Post-PV MF | Phase 3 | Recruiting | Kartos Therapeutics, Inc. | 600 | 2024-06-03 | 2025-09-25 |
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2024-05-23 | 2026-11-10 |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera Givinostat, Hydroxyurea - Polycythemia Vera | Phase 3 | Recruiting | Italfarmaco | 220 | 2024-03-26 | 2026-03-25 |
| Study of Olverembatinib (HQP1351) in Patients With CML-CP olverembatinib, Bosutinib - Chronic Myeloid Leukemia, CML | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 333 | 2024-02-05 | 2026-09-15 |
| Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera Open-label rusfertide - Polycythemia Vera | Phase 3 | Active not recruiting | Protagonist Therapeutics, Inc. | 46 | 2024-01-22 | 2025-08-06 |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 340 | 2023-12-31 | 2026-10-02 |
Showing 20 of 233. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (85) · Leukemia (71) · Leukemia, Myeloid, Acute (66) · Leukemia, Myeloid, Chronic-Phase (58) · Primary Myelofibrosis (58) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (52) · Myelodysplastic Syndromes (44) · Polycythemia Vera (35) · Leukemia, Myeloid, Accelerated Phase (32) · Lymphoma, Non-Hodgkin (31) · Thrombocythemia, Essential (31) · Hodgkin Disease (30) · Leukemia, Lymphocytic, Chronic, B-Cell (30) · Lymphoma (29)
Hemic and Lymphatic Diseases (233) · Hematologic Diseases (221) · Bone Marrow Diseases (219) · Neoplasms (175) · Neoplasms by Histologic Type (160) · Leukemia, Myeloid (151) · Pathological Conditions, Signs and Symptoms (139) · Chronic Disease (134) · Disease Attributes (134) · Pathologic Processes (134) · Leukemia (92) · Immune System Diseases (65) · Immunoproliferative Disorders (61) · Lymphatic Diseases (61)
Imatinib Mesylate (34) · Cytarabine (33) · nilotinib (26) · ruxolitinib (23) · Hydroxyurea (20) · Cyclophosphamide (19) · Peripheral Blood Stem Cell Transplantation (19) · Daunorubicin (18) · Etoposide (18) · Filgrastim (14) · Busulfan (13) · Methotrexate (13) · Dasatinib (12) · Radiotherapy (11) · Mitoxantrone (10)
Novartis Pharmaceuticals (28) · European Organisation for Research and Treatment of Cancer - EORTC (8) · AOP Orphan Pharmaceuticals AG (7) · Fred Hutchinson Cancer Center (7) · Alliance for Clinical Trials in Oncology (6) · Incyte Corporation (6) · Bristol-Myers Squibb (5) · Celgene (5) · Children's Oncology Group (5) · Merck Sharp & Dohme LLC (5) · Medical College of Wisconsin (4) · Eastern Cooperative Oncology Group (3) · Il-Yang Pharm. Co., Ltd. (3) · M.D. Anderson Cancer Center (3) · Medical Research Council (3)
United States (127) · Germany (75) · France (72) · Italy (69) · Canada (65) · United Kingdom (63) · Spain (54) · Belgium (52) · Australia (49) · Poland (45) · Austria (44) · Hungary (44) · Czechia (41) · Netherlands (40) · Israel (39)
Alan K. Burnett, MD, FRCP (3) · Heinz Gisslinger, MD (3) · Ruediger Hehlmann, MD (3) · Alan S. Gamis, MD, MPH (2) · Brenda Sandmaier (2) · Debra Barton, RN, PhD, AOCN, FAAN (2) · Mary Horowitz, MD (2) · Mary Horowitz, MD, MS (2)
PMID 31375516, PMID 36184192, PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 42316774, PMID 23515925, PMID 23620574, PMID 23911705, PMID 24859364, PMID 26069290, PMID 28273028, PMID 28962635, PMID 29396713, PMID 29926156, PMID 30523055, PMID 32499241, PMID 33275766, PMID 35235189, PMID 37267439, PMID 37553873, PMID 41890273, PMID 42452788, PMID 12637609, PMID 15010373, PMID 15459300, PMID 15761020, PMID 16484584, PMID 16932345, PMID 16960978, PMID 17151364, PMID 17315155, PMID 17339189, PMID 17397698, PMID 17715389, PMID 18256322, PMID 18430462, PMID 19117345, PMID 19264678, PMID 19270260, PMID 19291085, PMID 19369231, PMID 19648168, PMID 19710500, PMID 19797518, PMID 19826132, PMID 19965667, PMID 20038732, PMID 20117965
2023 (9), 2018 (4), 2014 (3), U01HL069294 (3), U10CA021115 (3), U10CA031946 (3), 2008 (2), 2009 (2), 2025 (2), P01CA018029 (2), P01CA078902 (2), P30CA015704 (2), P30CA068485 (2), U24CA076518 (2), 2004 (1)